How are digital biomarkers reshaping Parkinson’s disease research?
Bio Pharma Dive
JANUARY 30, 2023
Your Parkinson’s disease trials need better data. Hear how digital biomarkers change the game
Sat.Jan 28, 2023 - Fri.Feb 03, 2023
246 
HIV vaccines suffer setbacks but new approaches could turn the tide
Pharmaceutical Technology
FEBRUARY 3, 2023
Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. On January 18, Janssen, a Johnson & Johnson (J&J) subsidiary, stated that its vaccine was not effective in preventing HIV infections.
Join 15,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Can You Sue Your Doctor for Blindness Caused by Elmiron®?
Pharma Mirror
JANUARY 31, 2023
The Janssen Pharmaceuticals-produced medication Elmiron® is used to treat interstitial cystitis. Elmiron may be connected to eye damage that results in vision loss or other negative effects like blurry vision, according to some studies.
What happened to all the antibiotics?
Pharma Phorum
JANUARY 30, 2023
Across the world, there are reports of shortages of common antibiotics. Ben Hargreaves examines why these shortages are happening and what is being done in the background to return supply to normal. In many countries across the world, there are shortages of common antibiotics.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
This webinar will go over the FDA's guidance on pharmacological and toxicological considerations for optimizing doses for prescription drugs.
Biotech startup Structure pulls off rare IPO, raising $161M
Bio Pharma Dive
FEBRUARY 2, 2023
The company’s lead drug could be an oral alternative to marketed diabetes and obesity drugs from Novo Nordisk and Eli Lilly
uniQure signs license deal for Apic Bio’s gene therapy for SOD1-ALS
Pharmaceutical Technology
JANUARY 31, 2023
Gene therapy company uniQure has entered into a global licensing agreement with Apic Bio for APB-102 to treat patients with amyotrophic lateral sclerosis (ALS) caused by mutations in superoxide dismutase 1 (SOD1).
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
J&J's pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries
Fierce Pharma
FEBRUARY 3, 2023
J&J's pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries mbayer Fri, 02/03/2023 - 09:29
FDA to convene advisers on review of RSV vaccines from GSK, Pfizer
Bio Pharma Dive
FEBRUARY 1, 2023
The agency is currently assessing applications filed by the two companies for what they hope will become the first vaccines against the virus in older adults
US FDA approves GSK’s Jesduvroq to treat anaemia of CKD
Pharmaceutical Technology
FEBRUARY 2, 2023
The US Food and Drug Administration (FDA) has approved GlaxoSmithKline ’s (GSK) Jesduvroq (daprodustat) to treat anaemia caused by chronic kidney disease (CKD) in adults who have been on dialysis for at least four months.
Experts advise European SME packaging firms to expand or seek acquisition prior to Pharmapack Europe
Pharma Mirror
JANUARY 30, 2023
2022 Research: The Rapid Rise of Ocean Freight Visibility
Advertiser: FourKites
Download this a benchmark study from FourKites and The Journal of Commerce exploring how international shippers’ usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19.
Why we need to support healthcare’s vital acceleration
Pharma Phorum
JANUARY 29, 2023
What do I mean by vital acceleration? With the population ageing, the need for healthcare is growing fast: between 2015 and 2050, the proportion of the world’s population over 60 years old will nearly double from 12% to 22%, according to the World Health Organization.
Biotech CFOs eye research cuts, partnerships amid sector retrenchment: report
Bio Pharma Dive
JANUARY 30, 2023
The report, a yearly poll of 100 financing executives by accounting and consulting firm BDO, revealed the many levers young drugmakers are pulling to conserve cash
Pfizer reports 30% operational growth in full-year 2022 revenues
Pharmaceutical Technology
FEBRUARY 1, 2023
Pfizer has reported a 30% operational growth in revenues to $100.3bn in full-year 2022 compared with $81.2bn reported last year. The revenues grew 2% operationally excluding Paxlovid and Comirnaty’s contributions.
Vital NICE nod for Jazz’s Epidyolex
Pharma Times
FEBRUARY 1, 2023
UK-wide therapy for patients who have seizures linked to tuberous sclerosis complex
An Innovative & Creative Problem Solver Approach to Selling in the Medical Device Space
Speaker: Steve Goldstein, Sales Leader
Currently in sales or involved in a business that depends on strong sales results? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC. You will absorb critical strategies to become a trusted partner in greater sales success.
Pfizer warns Comirnaty sales will plummet by nearly two-thirds in 2023. And Paxlovid won't fare much better
Fierce Pharma
JANUARY 31, 2023
Pfizer warns Comirnaty sales will plummet by nearly two-thirds in 2023. And Paxlovid won't fare much better kdunleavy Tue, 01/31/2023 - 10:58
FDA approves cancer drugs from Lilly, Menarini
Bio Pharma Dive
JANUARY 30, 2023
The agency’s clearance of Jaypirca gives Lilly another win from its Loxo buyout, while Menarini Group’s bet on Radius Health’s oral SERD has now paid off with Orserdu’s OK
Magazine: CRISPR gene therapies cut through in 2023
Pharmaceutical Technology
FEBRUARY 2, 2023
If things go as per plan, in a few months, the US Food and Drug Administration (FDA) will deliberate on the first-of-its-kind CRISPR-based gene therapy for sickle cell disease (SCD) and transfusion-dependent beta thalassemia.
Milestone product launch for Kelso Pharma
Pharma Times
JANUARY 30, 2023
Acepiro tablets for respiratory diseases will be available across the UK prescription market
Mandatory COVID Vaccination Policy Template
Advertiser: Aggregage
The federal government is developing a rule requiring employers with more than 100 employees ensure their workers are vaccinated or produce a negative COVID test weekly before entering the workplace. So, what can your organization do to prepare? Get Paycor’s COVID Vaccination Policy Template to help communicate important details to your employees.
Pressure's on, GSK. Merck's Keytruda drops endometrial cancer win in first-line treatment
Fierce Pharma
FEBRUARY 3, 2023
Pressure's on, GSK. Merck's Keytruda drops endometrial cancer win in first-line treatment aliu Fri, 02/03/2023 - 09:43
Magenta to explore sale, merger after study setback
Bio Pharma Dive
FEBRUARY 3, 2023
The biotech recently stopped a trial of its experimental conditioning regimen over safety concerns. Now it’s halting further development work as it undertakes a strategic review
Merck reports 2% increase in worldwide sales in Q4 2022
Pharmaceutical Technology
FEBRUARY 3, 2023
Merck (MSD outside North America) has reported a 2% increase in worldwide sales to $13.83bn in the fourth quarter (Q4) of 2022 from $13.52bn in the previous year’s quarter. The company’s pharmaceutical sales recorded a 1% rise to $12.18bn compared to $12.03bn in the prior-year quarter.
Endevica Bio and Orbit Discovery unite to boost cachexia therapeutics
Pharma Times
FEBRUARY 2, 2023
The central focus of the agreement is to establish peptide hits from selected library populations
Aptamer partners with Hong Kong biotech to develop targeted gene therapies
BioPharma Reporter
JANUARY 31, 2023
UK based, Aptamer Group, and Hong Kong headquartered, BaseCure Therapeutics, are paring up on the development of Optimer-targeted gene therapies. Markets & Regulations
Karuna, hoping to find new brain drugs, buys up a shuttering biotech’s pipeline
Bio Pharma Dive
FEBRUARY 2, 2023
Though Goldfinch Bio focused on kidney diseases, Karuna believes its experimental drugs may have potential treating psychiatric and neurological conditions
Modernizing cell culture processes for the next wave of genomic medicine
Pharmaceutical Technology
FEBRUARY 3, 2023
The field of genomic medicine has reached a true turning point.
BaseCure collaborates with Aptamer Group to boost gene therapies
Pharma Times
FEBRUARY 1, 2023
Binders will establish cell types and delivery vehicles may increase uptake of the siRNA therapy
US senators raise concerns over Moderna’s planned COVID-19 vaccine price hike
BioPharma Reporter
JANUARY 30, 2023
US senators, Elizabeth Warren and Peter Welch, are urging Moderna to reconsider the proposed price increases for its COVID-19 vaccines. Markets & Regulations
A startup launches with plans to open up a gene and cell therapy bottleneck
Bio Pharma Dive
JANUARY 31, 2023
The pipeline of CAR-T therapies and ex vivo gene therapies has swelled in recent years, but manufacturing hasn’t been able to keep up with demand
Pharma sector reels as UK Government doubles VPAS payback rate on NHS drugs
Pharmaceutical Technology
JANUARY 30, 2023
The UK government’s decision to set an unprecedented payback rate of 26.5% on National Health Service (NHS) sales of branded medicines in 2023, almost double that of the previous year, has sent shock waves through the pharma industry.
Bill & Melinda Gates Foundation funding for MIP Discovery
Pharma Times
FEBRUARY 2, 2023
Boost concerns rapid deployment of novel detection reagents for testing in low to middle-income countries
Amgen's Humira biosimilar Amjevita hits the market with two different list prices
Fierce Pharma
JANUARY 31, 2023
Amgen's Humira biosimilar Amjevita hits the market with two different list prices zbecker Tue, 01/31/2023 - 10:58
COVID-19 vaccine maker Medicago to close down
Bio Pharma Dive
FEBRUARY 3, 2023
The company, which worked with GSK to develop a coronavirus shot, is ceasing operations after its corporate parent cut off further investment
US FDA grants breakthrough therapy designation for Moderna’s RSV vaccine
Pharmaceutical Technology
JANUARY 31, 2023
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Moderna ’s investigational mRNA vaccine candidate, mRNA-1345, for respiratory syncytial virus (RSV) in adult patients.
Let's personalize your content